Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02962362 · ClinicalTrials.gov registry record
Study to Assess Exactech's Guided Personalized Surgery eGPS® in Total Knee Arthroplasty
A clinical trial, sponsored by Exactech.
- Terminated
- Registry status
- 73
- Enrollment target
NCT02962362: Clinical Trial study, sponsored by Exactech.
NCT02962362 is a clinical trial that was terminated before completion, run by Exactech. The registered enrollment target is 73 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02962362 was terminated before completion, sponsored by Exactech.
- TERMINATED
- Registry status
- 73 participants
- Enrollment target
Study Summary
Study to collect outcomes data for patients who are undergoing an Exactech Optetrak® primary total knee replacement using the Exactech Guided Personalized Surgery (eGPS®) manufactured or distributed by (Exactech, Gainesville, Florida, USA).
Primary Outcome
total score, pain, function
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2016-08 |
| Est. Completion | 2021-11 |
Why NCT02962362 stopped before completion
NCT02962362 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 73 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT02962362 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02962362 about?
NCT02962362 is a clinical study titled "Study to Assess Exactech's Guided Personalized Surgery eGPS® in Total Knee Arthroplasty". Study to collect outcomes data for patients who are undergoing an Exactech Optetrak® primary total knee replacement using the Exactech Guided Personalized Surgery (eGPS®) manufactured or distributed by (Exactech, Gainesville, Florida, USA).
What is the current status of trial NCT02962362?
This trial is currently terminated. The enrollment target is 73 participants. The study started on 2016-08. Estimated completion is 2021-11.
Who is sponsoring clinical trial NCT02962362?
This trial is sponsored by Exactech, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03661307 · 73 participants · Phase 1
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
- NCT05386108 · 73 participants · Phase 1
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
- NCT05961592 · 73 participants · Phase 1
R-2487 in Patients With Rheumatoid Arthritis
- NCT06150664 · 73 participants · Phase 1
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia